"We Think There is a Good Chance of Broad-label Approval" - Needham & Company Bullish on Zealand Pharma (ZEAL) Following Phase 3 Data
Tweet Send to a Friend
Needham & Company analyst Joseph Stringer reiterated a Buy rating and $32.00 price target on Zealand Pharma A/S (NASDAQ: ZEAL) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
